How Does This Biotech Generate Growth?
Alnylam Pharmaceuticals develops and commercializes RNA interference (RNAi) medicines. Its business centers on bringing approved therapies to patients while advancing additional candidates through development. The company operates as a biotech focused on translating a platform technology into repeatable products. With a USD 39 billion market capitalization, it sits at a scale where funding choices can materially shape the path forward.
Are Profits Keeping Pace With Expansion?
FundamentalsIn USD reporting, 2025 revenue reached USD 3.7 billion alongside net income of USD 313.7 million. Profitability metrics over the trailing period show an 80.83% gross margin, with a 16.55% operating margin and a 13.46% net profit margin.
On the balance sheet, cash of USD 1.7 billion stands well above total debt of USD 225.1 million. Capital intensity looks contained, with depreciation and amortization of USD 55.7 million and capital expenditures of USD 58.7 million over the period.
Is The Market Overpaying For Momentum?
DCF / MultiplesAt USD 292.03 per share, the stock trades well below the DCF-derived fair value range. Headline multiples remain elevated, with a 66.58 P/E and 52.05 EV/EBITDA, placing a premium on continued earnings power.
Balance Sheet Supports Growth
TakeawayThe balance sheet looks built for endurance, with cash outweighing debt. The case depends on keeping revenue momentum while staying profitable. Funding pressure stays low if spending remains disciplined. If growth slows, today’s rich multiples become harder to justify.